Premium
(Des‐tyr 1 )‐gamma‐endorphin (DTγE) in the treatment of depression: Double‐blind placebo‐controlled trial
Author(s) -
Manchanda Rahul,
Hirsch Steven
Publication year - 1986
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470010207
Subject(s) - placebo , rating scale , double blind , medicine , psychology , depression (economics) , mood , psychiatry , developmental psychology , alternative medicine , pathology , economics , macroeconomics
Preliminary evidence of a mood‐elevating effect for the endogenous neuropeptide, (des‐tyr 1 )‐gamma‐endorphin, was further investigated in a double‐blind placebo‐controlled trial over a period of 2 weeks. There were 10 patients in each group. Between‐group comparisons on the change in scores by day 14 were non‐significant. There was, however, a significant reduction ( p = 0.05, two‐tailed) of scores on the Montgomery Asberg Depression Rating Scale and the anxious‐depression subscale of the BPRS in the endorphin group. It is recommended that the trial be conducted in a larger sample for definitive results.